John D. Morberg - 18 Jan 2024 Form 4 Insider Report for LIFECORE BIOMEDICAL, INC. \DE\ (LFCR)

Role
Chief Financial Officer
Signature
/s/ Aaron Perlitsh, Attorney-In-Fact for John Morberg
Issuer symbol
LFCR
Transactions as of
18 Jan 2024
Net transactions value
$0
Form type
4
Filing time
22 Jan 2024, 14:26:42 UTC
Previous filing
05 Jun 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction LFCR Common Stock Options Exercise +17,500 +15% 131,900 18 Jan 2024 Direct F1
transaction LFCR Common Stock Tax liability -6,283 -4.8% 125,617 18 Jan 2024 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction LFCR Restricted Stock Unit Options Exercise $0 -17,500 -100% $0.000000* 0 18 Jan 2024 Common Stock 17,500 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The restricted stock units convert into common stock of Lifecore Biomedical, Inc. on a 1 for 1 basis.
F2 The restricted stock units vested on January 18, 2024.